A Case of Triplet Therapy Showing Remarkable Efficacy for Multiorgan Metastatic Recurrence After Radical Prostatectomy in Prostate Cancer

Q4 Medicine

IJU Case Reports Pub Date : 2025-08-18 DOI:10.1002/iju5.70082

Shuhei Kusano, Shohei Tobu, Minika Yukimoto, Yukako Yamaguchi, Yuka Kakinoki, Akihiro Maeda, Maki Kawasaki, Hiroaki Kakinoki, Mitsuru Noguchi

{"title":"A Case of Triplet Therapy Showing Remarkable Efficacy for Multiorgan Metastatic Recurrence After Radical Prostatectomy in Prostate Cancer","authors":"Shuhei Kusano, Shohei Tobu, Minika Yukimoto, Yukako Yamaguchi, Yuka Kakinoki, Akihiro Maeda, Maki Kawasaki, Hiroaki Kakinoki, Mitsuru Noguchi","doi":"10.1002/iju5.70082","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>We report a case in which triplet therapy demonstrated efficacy for multiple metastatic recurrences following radical prostatectomy.</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>A 70-year-old man with relapsed metastatic castration-sensitive prostate cancer (mCSPC) following radical prostatectomy (Gleason 9, pT3bN1M0) presented with rectal involvement and extensive lymph node and bone metastases, as evidenced by a markedly elevated PSA level of 59.57 ng/mL. He received triplet therapy consisting of androgen deprivation therapy (ADT) with degarelix, darolutamide (1200 mg/day), and docetaxel (70 mg/m<sup>2</sup>). This combination led to a complete PSA response, dropping below the detection limit (< 0.006 ng/mL). At 24 months post-treatment, the patient remained in a stable condition without any signs of PSA recurrence.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This case highlights the potential of triplet therapy as a highly effective treatment strategy for high-risk mCSPC patients who experience recurrence after initial local therapy.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 5","pages":"517-520"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70082","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70082","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

We report a case in which triplet therapy demonstrated efficacy for multiple metastatic recurrences following radical prostatectomy.

Case Presentation

A 70-year-old man with relapsed metastatic castration-sensitive prostate cancer (mCSPC) following radical prostatectomy (Gleason 9, pT3bN1M0) presented with rectal involvement and extensive lymph node and bone metastases, as evidenced by a markedly elevated PSA level of 59.57 ng/mL. He received triplet therapy consisting of androgen deprivation therapy (ADT) with degarelix, darolutamide (1200 mg/day), and docetaxel (70 mg/m²). This combination led to a complete PSA response, dropping below the detection limit (< 0.006 ng/mL). At 24 months post-treatment, the patient remained in a stable condition without any signs of PSA recurrence.

Conclusion

This case highlights the potential of triplet therapy as a highly effective treatment strategy for high-risk mCSPC patients who experience recurrence after initial local therapy.

Abstract Image

查看原文本刊更多论文

三联疗法治疗前列腺癌根治性前列腺切除术后多器官转移复发疗效显著1例

我们报告了一例三联疗法对根治性前列腺切除术后多发性转移性复发的疗效。一名70岁男性根治性前列腺切除术（Gleason 9, pT3bN1M0）后复发转移性去势敏感前列腺癌（mCSPC），表现为直肠累及，广泛淋巴结和骨转移，PSA水平明显升高59.57 ng/mL。患者接受雄激素剥夺治疗（ADT）联合degarelix、darolutamide （1200mg /d）和docetaxel （70mg /m2）的三联治疗。这种组合导致PSA反应完全，低于检测限（0.006 ng/mL）。治疗后24个月，患者病情稳定，无PSA复发迹象。结论：该病例强调了三重疗法对于初始局部治疗后复发的高危mCSPC患者是一种非常有效的治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊